Satu Rapola
Research Subjects
Satu Rapola has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Aino K. Takala
2 shared publicationsHelena Käyhty
2 shared publicationsDavid E. Briles
University of Alabama , Birmingham
1 shared publicationGeorge M. Carlone
Centers for Disease Control and Prevention , Atlanta, Georgia
1 shared publicationJacquelyn S. Sampson
Centers for Disease Control and Prevention , Atlanta, Georgia
1 shared publicationJames C. Paton
Women's and Children's Hospital , Adelaide , Australia
1 shared publication
Latest Publications
- Open Access
- 15 December 2007
- Published by Taylor & Francis in International Journal of Circumpolar Health
- Vol. 66 (5) , 382-389
National immunization program in Finland
In the national immunization program, all Finnish children are vaccinated against 9 infectious diseases: diphtheria, tetanus, pertussis, polio, severe infections due to Haemophilus influenzae type b, measles, mumps, rubella and influenza. In addition, vaccination against tuberculosis, hepatitis A- and B-, influenza or tick-borne encephalitis are given to those at risk of contracting the diseases. More than 95% of children are vaccinated according the optimal schedule. Vaccine preventable diseases are rare in Finland. In Finland, all vaccines are imported. The decisions regarding the vaccination program are made by the Ministry of Social Affairs and Health. The National Public Health Institute is responsible for the control of the communicable diseases and the implementation of the vaccination program in practice. Evaluation of the implementation of new vaccines in the vaccination program is ongoing.
- 15 December 2007
- Published by Taylor & Francis in International Journal of Circumpolar Health
- Vol. 66 (5) , 382-389
Open AccessNational immunization program in Finland
In the national immunization program, all Finnish children are vaccinated against 9 infectious diseases: diphtheria, tetanus, pertussis, polio, severe infections due to Haemophilus influenzae type b, measles, mumps, rubella and influenza. In addition, vaccination against tuberculosis, hepatitis A- and B-, influenza or tick-borne encephalitis are given to those at risk of contracting the diseases. More than 95% of children are vaccinated according the optimal schedule. Vaccine preventable diseases are rare in Finland. In Finland, all vaccines are imported. The decisions regarding the vaccination program are made by the Ministry of Social Affairs and Health. The National Public Health Institute is responsible for the control of the communicable diseases and the implementation of the vaccination program in practice. Evaluation of the implementation of new vaccines in the vaccination program is ongoing.
- 1 September 2001
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 184 (5) , 577-581
Do Antibodies to Pneumococcal Surface Adhesin A Prevent Pneumococcal Involvement in Acute Otitis Media?
Antibodies to the pneumococcal (Pnc) surface protein PsaA are immunogenic and protective in experimental animal models, but their role in protection from Pnc disease in humans is not known. In the present study, the ability of antibodies to PsaA to prevent the progression of Pnc carriage to Pnc acute otitis media (Pnc AOM) was evaluated. Antibodies to PsaA were measured in acute-phase serum samples of children with AOM and with Streptococcus pneumoniae cultured from the nasopharynx. The risk of Pnc AOM was evaluated by a logistic regression model with anti-PsaA concentration as the predictive variable. Higher concentrations of antibodies to PsaA were associated with lower risk of the Pnc nasopharyngeal carriage progression to Pnc AOM. This was true in children 9–24 months old (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.31–0.78) but not in children <9 months old (OR, 0.81; 95% CI, 0.48–1.35)
- 1 September 2001
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 184 (5) , 577-581
Do Antibodies to Pneumococcal Surface Adhesin A Prevent Pneumococcal Involvement in Acute Otitis Media?
Antibodies to the pneumococcal (Pnc) surface protein PsaA are immunogenic and protective in experimental animal models, but their role in protection from Pnc disease in humans is not known. In the present study, the ability of antibodies to PsaA to prevent the progression of Pnc carriage to Pnc acute otitis media (Pnc AOM) was evaluated. Antibodies to PsaA were measured in acute-phase serum samples of children with AOM and with Streptococcus pneumoniae cultured from the nasopharynx. The risk of Pnc AOM was evaluated by a logistic regression model with anti-PsaA concentration as the predictive variable. Higher concentrations of antibodies to PsaA were associated with lower risk of the Pnc nasopharyngeal carriage progression to Pnc AOM. This was true in children 9–24 months old (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.31–0.78) but not in children <9 months old (OR, 0.81; 95% CI, 0.48–1.35)
- Open Access
- 1 October 2000
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 182 (4) , 1146-1152
Natural Development of Antibodies to Pneumococcal Surface Protein A, Pneumococcal Surface Adhesin A, and Pneumolysin in Relation to Pneumococcal Carriage and Acute Otitis Media
Pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), and pneumolysin (Ply) are common to virtually all Streptococcus pneumon
- 1 October 2000
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 182 (4) , 1146-1152
Open AccessNatural Development of Antibodies to Pneumococcal Surface Protein A, Pneumococcal Surface Adhesin A, and Pneumolysin in Relation to Pneumococcal Carriage and Acute Otitis Media
Pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), and pneumolysin (Ply) are common to virtually all Streptococcus pneumon